| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/16/2023 | -18.03% | Wells Fargo | → $4 | Downgrades | Equal-Weight → Underweight |
| 09/25/2023 | 104.92% | RBC Capital | → $10 | Reiterates | Outperform → Outperform |
| 08/31/2023 | 84.43% | Mizuho | $18 → $9 | Downgrades | Buy → Neutral |
| 08/22/2023 | 104.92% | Barclays | $12 → $10 | Maintains | Overweight |
| 08/21/2023 | 43.44% | JP Morgan | $9 → $7 | Downgrades | Neutral → Underweight |
| 08/14/2023 | 104.92% | RBC Capital | $12 → $10 | Maintains | Outperform |
| 08/11/2023 | 63.93% | B of A Securities | $9 → $8 | Downgrades | Neutral → Underperform |
| 08/11/2023 | — | Raymond James | Downgrades | Strong Buy → Underperform | |
| 06/23/2023 | 104.92% | Truist Securities | $9 → $10 | Maintains | Hold |
| 04/20/2023 | 84.43% | Wells Fargo | → $9 | Initiates Coverage On | → Equal-Weight |
| 04/19/2023 | 84.43% | Wells Fargo | → $9 | Initiates Coverage On | → Equal-Weight |
| 04/05/2023 | 145.9% | Barclays | $14 → $12 | Maintains | Overweight |
| 04/04/2023 | 207.38% | Keybanc | $16 → $15 | Maintains | Overweight |
| 03/31/2023 | 84.43% | Truist Securities | $8 → $9 | Maintains | Hold |
| 03/29/2023 | 63.93% | Truist Securities | $14 → $8 | Maintains | Hold |
| 03/16/2023 | 104.92% | B of A Securities | → $10 | Downgrades | Buy → Neutral |
| 03/07/2023 | 125.41% | Credit Suisse | → $11 | Reiterates | → Neutral |
| 03/03/2023 | 145.9% | JP Morgan | $14 → $12 | Maintains | Neutral |
| 03/02/2023 | 227.87% | Raymond James | $18 → $16 | Maintains | Strong Buy |
| 02/27/2023 | 186.89% | Barclays | $17 → $14 | Maintains | Overweight |
| 02/24/2023 | 125.41% | Credit Suisse | $13 → $11 | Maintains | Neutral |
| 01/27/2023 | 248.36% | Barclays | $19 → $17 | Maintains | Overweight |
| 01/19/2023 | 227.87% | Keybanc | $18 → $16 | Maintains | Overweight |
| 01/17/2023 | 166.39% | Credit Suisse | $11 → $13 | Maintains | Neutral |
| 12/21/2022 | 125.41% | Credit Suisse | $17 → $11 | Maintains | Neutral |
| 11/14/2022 | 227.87% | B of A Securities | → $16 | Upgrades | Neutral → Buy |
| 10/21/2022 | 289.34% | Barclays | $23 → $19 | Maintains | Overweight |
| 10/04/2022 | 268.85% | RBC Capital | $20 → $18 | Maintains | Outperform |
| 09/22/2022 | 268.85% | Raymond James | $20 → $18 | Maintains | Strong Buy |
| 09/16/2022 | 207.38% | Deutsche Bank | $17 → $15 | Maintains | Hold |
| 08/04/2022 | 371.31% | Barclays | $27 → $23 | Maintains | Overweight |
| 07/29/2022 | 309.84% | Mizuho | $26 → $20 | Maintains | Buy |
| 07/15/2022 | 309.84% | Raymond James | $24 → $20 | Maintains | Strong Buy |
| 07/14/2022 | 248.36% | Credit Suisse | $23 → $17 | Downgrades | Outperform → Neutral |
| 07/13/2022 | 248.36% | Deutsche Bank | $20 → $17 | Maintains | Hold |
| 07/07/2022 | 268.85% | Keybanc | $23 → $18 | Maintains | Overweight |
| 06/30/2022 | 207.38% | Jefferies | $19 → $15 | Maintains | Hold |
| 06/22/2022 | 268.85% | JP Morgan | $24 → $18 | Downgrades | Overweight → Neutral |
| 05/20/2022 | 350.82% | RBC Capital | $25 → $22 | Maintains | Outperform |
| 05/10/2022 | 391.8% | Raymond James | $26 → $24 | Maintains | Strong Buy |
| 05/02/2022 | 371.31% | Credit Suisse | $26 → $23 | Maintains | Outperform |
| 04/27/2022 | 309.84% | Deutsche Bank | $25 → $20 | Maintains | Hold |
| 04/27/2022 | 371.31% | Keybanc | $24 → $23 | Maintains | Overweight |
| 04/22/2022 | 309.84% | Jefferies | $25 → $20 | Downgrades | Buy → Hold |
| 03/24/2022 | 371.31% | Truist Securities | $26 → $23 | Maintains | Hold |
| 03/11/2022 | — | B of A Securities | Downgrades | Buy → Neutral | |
| 02/14/2022 | 432.79% | Credit Suisse | $27 → $26 | Maintains | Outperform |
| 02/01/2022 | — | Credit Suisse | Initiates Coverage On | → Outperform | |
| 01/03/2022 | 412.3% | Deutsche Bank | $27 → $25 | Downgrades | Buy → Hold |
| 10/29/2021 | 432.79% | Raymond James | $25 → $26 | Maintains | Strong Buy |
| 10/27/2021 | 391.8% | B of A Securities | $21.5 → $24 | Upgrades | Neutral → Buy |
| 10/26/2021 | 412.3% | Raymond James | → $25 | Initiates Coverage On | → Strong Buy |
| 08/11/2021 | 371.31% | RBC Capital | → $23 | Upgrades | Sector Perform → Outperform |
| 07/14/2021 | 371.31% | Mizuho | → $23 | Assumes | → Buy |
| 07/06/2021 | 340.57% | B of A Securities | → $21.5 | Downgrades | Buy → Neutral |
| 06/15/2021 | 371.31% | Wolfe Research | → $23 | Initiates Coverage On | → Peer Perform |
| 05/03/2021 | 371.31% | RBC Capital | $24 → $23 | Downgrades | Outperform → Sector Perform |
| 01/22/2021 | 350.82% | Truist Securities | → $22 | Downgrades | Buy → Hold |
| 01/21/2021 | 391.8% | KeyBanc | $22 → $24 | Maintains | Overweight |
| 12/15/2020 | 391.8% | Deutsche Bank | → $24 | Upgrades | Hold → Buy |
| 09/02/2020 | 330.33% | Stifel | → $21 | Reinstates | → Buy |
| 08/24/2020 | 371.31% | Mizuho | $20 → $23 | Upgrades | Neutral → Buy |
| 07/10/2020 | 289.34% | Deutsche Bank | $23 → $19 | Downgrades | Buy → Hold |
| 06/25/2020 | 309.84% | SunTrust Robinson Humphrey | $19 → $20 | Maintains | Buy |
| 04/23/2020 | 289.34% | SunTrust Robinson Humphrey | $22 → $19 | Maintains | Buy |
| 04/21/2020 | 309.84% | Keybanc | $25 → $20 | Maintains | Overweight |
| 04/03/2020 | 227.87% | Wells Fargo | $21 → $16 | Maintains | Equal-Weight |
| 04/03/2020 | 309.84% | JP Morgan | $25 → $20 | Maintains | Overweight |
| 03/30/2020 | 289.34% | Mizuho | → $19 | Downgrades | Buy → Neutral |
| 01/16/2020 | 371.31% | Keybanc | $22 → $23 | Maintains | Overweight |
| 01/14/2020 | 350.82% | Baird | $20 → $22 | Maintains | Neutral |
| 12/26/2019 | 432.79% | Mizuho | $25 → $26 | Maintains | Buy |
| 12/20/2019 | 412.3% | Mizuho | → $25 | Initiates Coverage On | → Buy |
| 10/14/2019 | 299.59% | B of A Securities | → $19.5 | Initiates Coverage On | → Neutral |
| 09/12/2019 | 350.82% | Berenberg | → $22 | Initiates Coverage On | → Buy |
| 09/03/2019 | 309.84% | Barclays | → $20 | Initiates Coverage On | → Overweight |
| 08/27/2019 | 330.33% | SunTrust Robinson Humphrey | $20 → $21 | Maintains | Buy |
| 08/07/2019 | 309.84% | Keybanc | → $20 | Upgrades | Sector Weight → Overweight |
| 07/24/2019 | 289.34% | Stifel | $18 → $19 | Upgrades | Hold → Buy |
| 07/02/2019 | 309.84% | SunTrust Robinson Humphrey | $19 → $20 | Upgrades | Hold → Buy |
| 03/29/2019 | 227.87% | Deutsche Bank | $14 → $16 | Maintains | Hold |
| 02/13/2019 | 371.31% | Jefferies | $18 → $23 | Upgrades | Hold → Buy |
| 12/11/2018 | 258.61% | Wells Fargo | $13.5 → $17.5 | Upgrades | Underperform → Market Perform |
What is the target price for Medical Properties Trust (MPW)?
The latest price target for Medical Properties Trust (NYSE: MPW) was reported by Wells Fargo on October 16, 2023. The analyst firm set a price target for $4.00 expecting MPW to fall to within 12 months (a possible -18.03% downside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Medical Properties Trust (MPW)?
The latest analyst rating for Medical Properties Trust (NYSE: MPW) was provided by Wells Fargo, and Medical Properties Trust downgraded their underweight rating.
When is the next analyst rating going to be posted or updated for Medical Properties Trust (MPW)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medical Properties Trust, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medical Properties Trust was filed on October 16, 2023 so you should expect the next rating to be made available sometime around October 16, 2024.
Is the Analyst Rating Medical Properties Trust (MPW) correct?
While ratings are subjective and will change, the latest Medical Properties Trust (MPW) rating was a downgraded with a price target of $0.00 to $4.00. The current price Medical Properties Trust (MPW) is trading at is $4.88, which is out of the analyst's predicted range.